BIND Therapeutics Announces Departure of Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

BIND Therapeutics, Inc. BIND, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins^TM, today announced that Greg Berk, M.D., Chief Medical Officer, will be leaving BIND to pursue another opportunity. Dr. Berk will serve as an advisor to BIND after his departure.

"Our clinical team is focused on the Phase 2 clinical trials for our lead product candidate, BIND-014, which continues to enroll patients in line with our expectations,” commented Scott Minick, President and Chief Executive Officer of BIND. “We look forward to reporting clinical results and our progress on developing the platform later this year.”

“BIND's Accurin platform represents an exciting opportunity, and I have very much enjoyed the experience of working with the accomplished BIND team to translate this technology into the robust clinical program that is ongoing today,” said Dr. Berk. “I remain enthusiastic about the potential clinical benefit that BIND-014 can bring to patients and look forward to remaining involved in an advisory role.”

The Company is initiating a search for a new chief medical officer. Edward Schnipper, M.D., who has been serving as an advisor to BIND and formerly served as BIND's chief medical officer, will serve as the company's chief medical officer on an interim basis.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineering^® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. BIND has announced collaborations with Amgen Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND's platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women's Hospital/Harvard Medical School of BIND's scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the company's web site at www.bindtherapeutics.com.